Immunogenicity and Safety Study of SCB-2019 Vaccine as a Booster to COVID-19 Vaccine in Adults

Summary

The purpose of this study is to assess the immunogenicity and safety of the investigational SCB-2019 vaccine, administered as a booster dose, to adults who: * Received primary series with one of the selected authorized or investigational COVID-19 vaccines at least 3 months prior to enrollment. * Received primary series and a booster dose of CoronaVac at least 3 months prior to enrollment.

Timeline

Start

2022-06-13

Primary completion

2023-06-06

Completion

2023-06-06

Publications

• Roa CC Jr, de Los Reyes MRA, Plennevaux E, Smolenov I, Hu B, Gao F, Ilagan H, Ambrosino D, Siber G, Clemens R. Superior Boosting of Neutralizing Titers Against Omicron SARS-CoV-2 Variants by Heterologous SCB-2019 Vaccine vs a Homologous Booster in CoronaVac-Primed Adults. J Infect Dis. 2023 Nov 2;228(9):1253-1262. doi: 10.1093/infdis/jiad262.

Drugs

Indications